scholarly journals PCOS

2018 ◽  
Vol 25 (04) ◽  
pp. 568-572
Author(s):  
Ayesha Tariq ◽  
Muhammad Azeem Mir ◽  
Saba Babar ◽  
Rahat Akhtar

Objectives: The objective is to compare the efficacy of Pioglitazone andMetformin for ovulation in patients of polycystic ovarian syndrome. Study Design: Randomizedcontrol trial. Setting: Department of Obstetrics and Gynecology, Nishtar Hospital Multan. Period:January 2017 to June 2017. Methodology: Total number of 66 patients was recruited for thisstudy. These patients were admitted through or outpatient department. Group A and Group B,33 patients each. In Group-A patients received metformin while in Group B pioglitazone wasadministered. Sample size was calculated using the reference study by Chaudhry I et al (9)using sample size calculator for two proportions (power of study 80% and confidence interval95% where prevalence (P1) was 52.17% and (P2) 75%). In group-A patients, Metformin withdose of 1500 mg per day in three divided doses were given for 6 months. In group B patients,Pioglitazone 15mg was administered for 6 months. At the end of 6 months, all the patients wereevaluated for efficacy. Results: Total no. of 66 patients was included. The mean age and BMIof the patients was 29.35±4.01 years and 29.74±2.75 kg/m2 respectively. The age distributionnoted as 66.7% (n=44) patients between 18-30 years and 33.3% (n=22) between 31-37 years.BMI distribution observed as 45.5% (n=30) patients between 24-29 kg/m2 and 54.5% (n=36)patients between 30-34 kg/m2. These 100% (n=66) patients were divided into 2 groups equally,33 in each, i.e. group A and group B. The mean age and BMI of the patients of group Awas 29.42±4.32 years and 29.87±2.58 kg/m2 respectively, while the mean age and BMI ofthe patients of group B was 29.27±3.75 years and 29.60±2.94 kg/m2 respectively. Ovulationwas noted as 42.4% (n=14) and 45.5% (=15) for groups A and B respectively. No associationwas found between efficacy and ovulation (p=0.849). Efficacy was notes as 69.7% (n=23) and72.7% (n=24) for group A and group B respectively. No difference was found between efficacyand groups i.e. between pioglitazone and metformin for ovulation in patients of polycystic ovarysyndrome (p=0.786). Similarly, no association was found between efficacy with age (p=0.442)and BMI (p=0.728), after applying the chi-square. Conclusion: This study concludes thatPioglitazone is as much effective as metformin for ovulation induction in women with PCOS.

Esculapio ◽  
2021 ◽  
Vol 16 (4 (oct 2020 - dec 2020)) ◽  
Author(s):  
Zubda Aiman ◽  
Amna Khanam ◽  
Mahliqa Maqsood ◽  
Mehwish ayyaz ◽  
Miss Alia ◽  
...  

Objective: To compare the frequency of Ovulation Induction after administration of Letrozole with metformin versus Letrozole alone in females presenting with Polycystic Ovarian Syndrome Methods: This Randomized Controlled Trial was done in unit 5 of Lady Aitchison Hospital Lahore for 6 months. Total 200 females fulfilling the inclusion criteria were recruited from OPD. Lottery method was used for randomization of study subjects. Females in group A were given Letrozole 2.5mg once a day for five days (from third to seventh day)of the cycle for three consecutive months and metformin 1500mg (500mg 3 times a day) daily for three months, while females in group B were given Letrozole 2.5mg once a day for five days (from third to seventh day) le for three consecutive months. Then they were followed up in OPD for 3 cycles. In all 3 cycles TVS was done on day 12 to access the number of follicles and to measure the size of largest follicle, and on day 21 of cycle progesterone level will be assessed for confirmation of ovulation induction. The data was entered and analyzed through SPSS version 20. Mean and standard deviation was calculated for age and BMI. Frequency and percentage was calculated for Ovulation induction. Both groups were compared by using chi-square test taking p-value<0.05 as significant. Data was stratified for BMI (Normal, overweight and Obese).After stratification chi-square test was applied keeping a p value < 0.05 as significant. Results: In Group-A mean age of women was 28.18±6.58 years. In Group-B mean age of women was 27.08±5.15 years. In Group-A ovulation induction rate was much higher as compared to that of Group-B women. i.e. (89% vs. 60%). p-value=0.000. Ovulation induction rate was significantly higher with Letrozole+ Metformin in women who were having normal BMI, overweight & obese as compared to that of Letrozole alone. Conclusion: Letrozole with metformin is more effective for the ovulation Induction females presenting with polycystic ovarian Syndrome as compared to letrozole alone.() Key Words: Polycystic Ovarian Syndrome, Management, Ovulation Induction, Letrozole, Metformin How to Cite: Aiman Z, Khanam A, Maqsood M, Ayyaz M, Alia, Kanwal K. Comparison of ovulation induction with letrozole with metformin versus letrozole alone in females presenting with polycystic ovarian syndrome. Esculapio.2020;16(04):54-58.


2021 ◽  
Vol 71 (5) ◽  
pp. 1844-47
Author(s):  
Amna Shafiq ◽  
Rabiya Akbar ◽  
Uzma Urooj ◽  
Sadaf Zohra ◽  
Shazia Afzal ◽  
...  

Objective: To compare the ovulation induction of letrozole and clomiphene citrate in sub-fertile women with polycystic ovarian syndrome. Study Design: Quasi experimental study. Place and Duration of Study: Combined Military Hospital Rawalpindi, from Jun 2018 to Aug 2019. Methodology: A total of 116 married sub-fertile women with polycystic ovarian syndrome, 16-40 years of age were included. Patients with previous surgery related to genital tract, hypothyroidism and chronic renal failure were excluded. Letrozole 5.0mg daily from Day 5-9 of menstruation was prescribed to group A women and clomiphene citrate 100 mg daily from Day 5-9 of menses was given to group B women. Results: In group A and in group B, mean age was 29.78 ± 4.71 years and 29.95 ± 4.22 years respectively. Most of the patients 59 (50.86%) were between 18-30 years of age. Mean duration since marriage was 4.23 ± 1.42 years. Mean body mass index was 29.71 ± 2.65 kg/m2. Frequency of ovulation of clomiphene citrate and letrozole in sub-fertile women with polycystic ovaries was 28 (42.28%) versus 42 (72.41%) respectively (p-value=0.008). Conclusion: This study concluded that ovulation induction of letrozole is better than clomiphene citrate in sub-fertile women with polycystic ovarian syndrome.


Author(s):  
Sumreen Anjum ◽  
Afshan Ambreen ◽  
Munazzah Bashir ◽  
Asiya Nawaz Alvi ◽  
Aasma Hanif ◽  
...  

Background: Polycystic ovarian syndrome (PCOS) is a genetically heterogeneous syndrome in which females often have to confront with the issue of infertility. Medical management of PCOS is aimed at the treatment of anovulation and menstrual irregularity. Letrozole and clomiphene citrate are two successful drugs for management of PCOS but contradiction is present in literature that which drug is more effective. So we conducted this study to find more successful drug to be implemented in future in local population. Objective: To compare the efficacy of oral Letrozole versus Clomiphene Citrate in females diagnosed with infertility due to polycystic ovaries Subjects & Methods: This randomized control trial was conducted at department of Gynaecology & Obstetrics, Fatima Memorial Hospital, Lahore for 6 months (May to November 2020). The non-probability, consecutive Sampling was used. Informed consent and demographic data was noted. Then females were randomly divided in two group by using lottery method. Females in Letrozole group were prescribed 2.5-7.5 mg daily from Day 2-Day 6 of menstruation and females in clomiphene citrate group was prescribed 50-150 mg daily from Day 2-Day 6 of menses. Females were advised to visit after every cycle till 3months. On every visit transvaginal ultrasonography was done to assess presence of follicles and number and size of follicles and endometrial thickness. All the data was entered on SPSS version 20. Results: The mean age of the patients was 26.13±5.07 years in group A and 27.17±5.95 years in group B. After 3rd month, the mean endometrial thickness in group A was 8.45±0.58 mm and in group B was 7.45±0.58 mm, the mean follicle was 23.75±4.253 in group A while 20.38±6.154 in group B. The ovulation occurred in 48 cases in group A and in 29 cases in group B. The efficacy was achieved in 36 cases in group A and 16 cases in group B and the difference in both groups was statistically significant i.e. p-value=0.000. Conclusion: Thus the Letrozole has significantly higher efficacy as compared to Clomiphene citrate. So from the results of our study we recommend letrozole as first line treatment for the management of PCOS. Keywords: Polycystic ovarian syndrome, PCOS, Letrozole, Clomiphene Citrate, Efficacy, Infertility


2021 ◽  
Vol 15 (6) ◽  
pp. 1494-1496
Author(s):  
T. Akhtar ◽  
F. Shaikh ◽  
Basma . ◽  
W. U. N. Ahmed ◽  
S. Lashari ◽  
...  

Objective: To compare the efficacy of insulin sensitizer myoinositol versus a combination of myoinositol plus metformin for ovulation induction in polycystic ovarian syndrome. Study Design: Prospective, randomize control trail. Place & Duration of Study: Department of Obstetrics & Gynaecology, Sheikh Zayed Women Hospital Larkana from 1st January 2017 to 31st December 2017. Methodology: Sixty patients were recruited. The proper clinical history, demographic and physical examinations were recorded. Sixty patient divided in two groups A and B, each group receive 30 patients. Group A received myoinositol 1 gm twice daily plus ovulation (letrozole +gonadotrophin) and Group B received two insulin sensitizer myoinositol and metformin plus ovulation induction protocol(from 2-6 days and 7-9 days. Transvaginal ultrasound performed on day 12 of all patients to see the follicular size. Results: Mean age of participants was 26.4±4.4 years and LH/FSH ratio was >1.5. Oligomenorrhea, infertility, hirsutism, and overweight were the major clinical manifestation of women with PCOs. Twenty nine women with PCOs of group A (metformin plus myoinositol) were increased number of follicles as compared to women of group B (myoinositol alone), the difference was statistically significant (p<0.05). Conclusion: The combination of these two drugs ‘Metformin and Myoinositol’, work synergistically that gives more metabolic and reproductive benefits as compared to single drug work alone. Keywords: Polycystic ovarian syndrome, Ovulation, Metformin, Myoinositol, Insulin sensitivity


2021 ◽  
Vol 15 (10) ◽  
pp. 2685-2688
Author(s):  
Tehmina Zafar ◽  
Fiza Asif ◽  
Rubina Naurin ◽  
Tayyaba Majeed ◽  
Zahid Mahmood

Background: Anovulation is the commonest cause of female infertility and polycystic ovarian syndrome (PCOS) is the most frequently seen cause of anovulation among infertile females. Letrozole and Clomiphene Citrate are two common drugs for PCOS. But controversial data was noticed regarding their effectiveness. Aim: To compare effectiveness of Letrozole versus Clomiphene Citrate to evaluate the ovulation induction in patients with polycystic ovarian syndrome Methods: After fulfilling the selection criteria, total 360 females were enrolled according to calculated sample size and were randomly divided into two equal groups. One is treated with letrozole and other is clomiphene citrate. Successful ovulation was noted on follow up. Data was collected in proforma and later on analyzed in SPSS version 23. Results: The mean age of patients in letrozole group was 26.61± 4.81 years and in clomiphene citrate was it 27.89±4.24 years. Successful ovulation induction was noted in 172 with letrozole and 150 with clomiphene citrate i. e p-value=0.001. Conclusion: Letrozole has significantly better efficacy for successful ovulation than Clomiphene Citrate for PCOS. Keywords: Ovulation, Clomiphene citrate, Letrozole, polycystic ovarian syndrome


2021 ◽  
Vol 8 (4) ◽  
pp. 553-558
Author(s):  
Manish R Pandya ◽  
Khushbu Patel

Clomiphene citrate has been traditionally used as the drug of the choice for treatment of women with anovulatory infertility. In the last decade, an aromatase inhibitor, letrozole has emerged as an alternative ovulation induction agent among anovulatory women with polycystic ovarian syndrome. Letrozole has a definitive role in anovulatory women who have not responded to the clomiphene citrate therapy is confirmed by literatures. Anovulatory dysfunction is a common problem and is responsible for about 40% of female infertility and among causes; PCOS (polycystic ovarian syndrome) is the leading cause. Clomiphene citrate is considered as the drug of choice for the first line treatment of anovulatory dysfunction for a variety of reasons. Clomiphene citrate has some side effects like multi-follicular development and cyst formation and resistance of clomiphene are areas of concern and desire for an effective alternative persists.An aromatase inhibitor, letrozole, was introduced into infertility practice in the year 2000 and is regarded as a second line option, particularly in women with clomiphene resistance, and it has found acceptance in various clinical situations and the indications for use have expanded., To compare the efficacy of letrozole and clomiphene citrate (CC) for ovulation induction in infertile women. The study included 100 women presented with anovulatory infertility. The infertile women were divided into 2 groups of 50: Group A received 100 mg Clomiphene Citrate from day 3 to day 5 of menstruation and Estradiol Valerate 4 mg on the 12 day of menstruation until 16 day of menstruation; Group B treated by 5 mg Letrozole from day 3 to day 5 of the menstruation and as Group A, Estradiol Valerate 4 mg on the 12 day of menstruation until 16 day of menstruation given to Group B, with visits to determine ovulation and pregnancy, followed by tracking of pregnancies. Participants were of 20 to 39 years age, had normal uterine cavity and had a male partner with a sperm concentration of at least 14 million per millilitre; and during the study the women and their partners agreed to have regular intercourse with the intent of conception. The live birth during the treatment period was the primary outcome. Women who received letrozole had more cumulative live births than those women who had received clomiphene citrate (36 out of 50 [72%] vs. 28 out of 50 [56%]), without significant differences in overall congenital anomalies, there were no congenital anomalies. With letrozole as compared to clomiphene the cumulative ovulation rate was higher. Higher incidence of hot flushes was associated with a clomiphene, and letrozole was associated with fatigue and dizziness. Rates of other adverse effects were almost similar among these 2 groups. A significant difference in the follicular and endometrial development was evident among these 2 groups. As compared to with clomiphene, an aromatase inhibitor, letrozole was associated with higher live-birth and ovulation rates among infertile women. The results of the study demonstrated letrozole to be superior to clomiphene citrate in the maintenance of endometrial thickness.


2021 ◽  
Vol 28 (05) ◽  
pp. 749-754
Author(s):  
Nadia Sharif ◽  
Uzma Manzoor ◽  
Saadia Bano ◽  
Uzma Shahzaad

Objective: To compare the efficacy of Letrozole and clomiphene citrate in Patients of Anovulation polycystic ovarian syndrome with Infertility. Study Design: Randomized Controlled Trial Setting: Department of Obstetrics and Gynecology Independent Medical College Faisalabad. Period: 30-09-2019 to 29-6-2020. Material & Methods: This study included 100 patients with 50 patients in each group. Group A received 2.5 to 5mg letrozole in each cycle from day 3 to 7. Group B received clomiphene citrate 50 to 100 mg incremental dose depending on ovarian response. Both Drugs were given for consecutive 3 to 6 cycles to see response. Main outcome Measure included optimal follicle size (> 18mm), endometrial thickness, and pregnancy rate. Epidemiological data and efficacy outcome measures were recorded on a Performa. Statistical analysis was done using SPSS version 13. Chi-square test applied and p-value <o.o5 was considered significant. Both group included primary infertility patients. Results: The mean age of patients was 28.03+ 3.02 years. Mean age of group A patients was 29.04+3.44 and 28.47+3.90 group B patients. Mono ovulation in group A patients (88.9%) and 27 in group b patients (60.0%). The mean endometrial thickness was 9.6mm + 1.6 in letrozole group and 6.9mm + 1.2 in clomiphene citrate group A. In group A 18% got pregnant from Letrozole group and 1.1% from the group B. Conclusion: Efficacy was significantly higher in group A Patients received letrozole as compared to patients echo received clomiphene citrate. The effects of Letrozole showed better outcome in terms of Ovulation Induction Endometrial Thickness and Pregnancy rate.


Author(s):  
Fadia J Alizzi

Objectives: The objective is to evaluate the clinical outcome of using letrozole alone or with gonadotropin as first-line ovulation induction in anovulatory infertile polycystic ovary women. Methods: A prospective single-arm study. 80 infertile polycystic ovarian syndrome (PCOS) women had been recruited between January and October 2017. Letrozole on day 2–3 of the cycle was given. The women are sorted into two groups according to the size of the dominant follicle on day 7 or 8, Group A (letrozole only group) and Group B (letrozole plus gonadotropin).Results: In our study, the overall pregnancy rate was (67.5%) and ovulation rate was 91.3%. The ovulation rate was significantly higher in Subgroup A than B (97.9% vs. 81.3%). Pregnancy rate was higher in Subgroup A (72.9% vs. 59.4%), but it was statistically not significant. The number of follicles was significantly higher in Subgroup B. Endometrial thickness, miscarriages, ovarian hyperstimulation syndrome, and multiple pregnancies were not statistically significant. Lower cycle number independently and significantly predict clinical pregnancy, while body mass index has a modest effect.Conclusions: Letrozole alone or in combination with gonadotropin as a first-line treatment in PCOS may be reasonable since this approach may improve the success rate and minimize the overall costs and risks. 


Biomedicine ◽  
2020 ◽  
Vol 39 (4) ◽  
pp. 608-612
Author(s):  
Veena Kirthika S. ◽  
Jibi Paul ◽  
Senthil Selvam P. ◽  
Sathya Priya V.

Introduction and Aim: Polycystic ovarian syndrome (PCOS) is a heterogenous, multisystem endocrinopathy in women of reproductive age also called as Stein Leventhal syndrome. PCOS is a common female endocrine disorder with prevalence ranging from 2.2% to 26%. Prevalence of PCOS in Indian adolescents is 9.13%. This draws attention to the issue of early diagnosis in adolescent girls. The aim of this study was to determine the effect of progressive resisted exercises (PRE) and aerobic exercises in the management of subjects with PCOS. Materials and Methods: This was an experimental comparative pre and post-test type study. The subjects in the age group of 18-25 years with the diagnosis of PCOS were selected based on Rotterdam criteria and with the BMI ranging between 25-29. Twenty four subjects were recruited and were randomly divided into two groups. group A was treated with PRE +aerobic exercises + diet and group B with aerobic exercises + diet. The duration of the study was 24 weeks and the outcome measures used were BMI, PCOSQ and hormonal levels (SHBG, Free testosterone, HOMA IR, Hs CRP) Results: The result of the study showed that group A treated with PRE + aerobic exercises + diet had significant improvement in BMI at P?0.05 and PCOSQ and specific hormonal levels at P?0.001 when compared to group B. Conclusion: A 24 weeks exercise intervention with a combined PRE +aerobic exercises +diet was superior to aerobic exercises +diet among young subjects with PCOS. Keywords: BMI; quality of life; PRE; PCOSQ; Hormones.


2017 ◽  
Vol 24 (09) ◽  
pp. 1331-1335
Author(s):  
Khalid Hussain ◽  
Maria Tarique ◽  
Attiq ur Rehman Khan ◽  
Asim Bukhari ◽  
Bilal Akhter ◽  
...  

Objectives: To compare Tamsulosin versus ESWL for lower ureteric stonesexpulsion. Study Design: Randomized controlled trial. Setting: Outpatient Department ofUrology at Services Hospital, Lahore. Period: January 2015 to December 2015. Material& Methods: Total 50 patients were enrolled in study. Patients were divided into 2 groups.In group A, 25 patients received daily oral treatment of 0.4mg Tamsulosin for 28 days, andin group B, 25 patients were treated with ESWL. A stone-free condition, was defined as thecomplete absence of any stone based on plain abdominal X-rays observed and during followupvisits at the time of treatment of stone was noted. Results: The mean age of the patientswere recorded as 33.20±9.23 years. There were 40(80%) males and 10(20%) females with maleto female ratio of 4:1. Out of 50 patients, 16(32%) presented with hematuria, 3(6%) had feverwhile 31(62%) appeared with no complication status. Out of 50 patients, 21(42%) presentedwith expulsion time 08-14 days in which 14(28%) were from tamsulosin group and 07(14%)were from ESWL group, similarly 19(38%) patients appeared with expulsion time of 15-28 daysin which 10(20%) were from tamsulosin group and 09(18%) were from ESWL group. Statisticallythere is insignificant difference between the groups i.e. p-value=0.28 Ns. Conclusion: Thisstudy suggests that the tamsulosin helps in the earlier clearance of stone fragments andreduces the complications as compared to ESWL.


Sign in / Sign up

Export Citation Format

Share Document